Treasurer of the State of North Carolina Purchases 640 Shares of Certara, Inc. (NASDAQ:CERT)

Treasurer of the State of North Carolina boosted its position in shares of Certara, Inc. (NASDAQ:CERT – Get Rating) by 1.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 50,444 shares of the company’s stock after purchasing an additional 640 shares during the period. Treasurer of the State of North Carolina’s holdings in Certara were worth $811,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Clearbridge Investments LLC boosted its stake in shares of Certara by 58.7% during the first quarter. Clearbridge Investments LLC now owns 3,200,895 shares of the company’s stock valued at $68,755,000 after purchasing an additional 1,183,859 shares during the period. AEGON ASSET MANAGEMENT UK Plc purchased a new stake in Certara in the 4th quarter valued at about $17,824,000. Massachusetts Financial Services Co. MA grew its stake in Certara by 40.2% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 2,884,968 shares of the company’s stock worth $38,312,000 after acquiring an additional 827,191 shares in the last quarter. Edmond DE Rothschild Holding S.A. increased its position in shares of Certara by 1,071.7% during the fourth quarter. Edmond DE Rothschild Holding S.A. now owns 765,446 shares of the company’s stock worth $12,301,000 after acquiring an additional 700,117 shares during the period. Finally, Fort Washington Investment Advisors Inc. OH purchased a new position in shares of Certara during the fourth quarter worth approximately $10,998,000. 75.45% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Certara

In other news, SVP Richard M. Traynor sold 5,000 shares of the business’s stock in a transaction dated Thursday, May 11th. The stock was sold at an average price of $20.82, for a total transaction of $104,100.00. Following the sale, the senior vice president now owns 177,368 shares in the company, valued at $3,692,801.76. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 2.60% of the stock is currently owned by corporate insiders.

Certara Trading Up 1.5 %

NASDAQ CERT opened at $20.10 on Monday. Certara, Inc. has a 52 week low of $10.60 and a 52 week high of $24.96. The company has a 50 day moving average price of $22.87 and a 200 day moving average price of $19.29. The company has a quick ratio of 3.71, a current ratio of 3.71 and a debt-to-equity ratio of 0.27. The firm has a market cap of $3.21 billion, a PE ratio of 223.33, a price-to-earnings-growth ratio of 1.13 and a beta of 1.57.

Certara (NASDAQ:CERT – Get Rating) last released its quarterly earnings results on Monday, May 8th. The company reported $0.12 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.12. Certara had a net margin of 4.03% and a return on equity of 5.53%. The business had revenue of $90.30 million for the quarter, compared to analyst estimates of $91.29 million. During the same period in the previous year, the company earned $0.11 earnings per share. The business’s revenue for the quarter was up 10.7% on a year-over-year basis. As a group, sell-side analysts forecast that Certara, Inc. will post 0.37 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have commented on the company. Stephens started coverage on Certara in a report on Tuesday, April 11th. They set an “overweight” rating and a $28.00 price objective on the stock. TheStreet raised shares of Certara from a “d+” rating to a “c” rating in a research note on Monday, April 10th. Credit Suisse Group raised their target price on shares of Certara from $22.00 to $27.00 in a research report on Monday, March 27th. Morgan Stanley upped their price target on shares of Certara from $20.00 to $21.00 and gave the stock an “equal weight” rating in a research report on Friday, March 10th. Finally, Barclays lowered shares of Certara from an “overweight” rating to an “equal weight” rating and lifted their price objective for the company from $21.00 to $25.00 in a report on Monday, April 3rd. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $24.25.

Certara Profile

(Get Rating)

Certara, Inc provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development.